LW 108
Alternative Names: LW-108Latest Information Update: 11 Mar 2024
At a glance
- Originator Longwood Biopharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis modulators; Proto-oncogene protein c-mdm2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 27 Feb 2024 LW 108 is available for licensing as of 27 Feb 2024. https://www.lwbpsh.com/en/research#collaboration
- 31 Dec 2022 Preclinical trials in Solid tumours in China (PO) prior to December 2022 (Longwood Biopharma website, February 2024)